Эффективность затрат на ингибиторы тирозинкиназы при хроническом Ph-позитивном миелолейкозе, резистентном к иматинибу

1. Стандарт медицинской помощи больным с миелолейкозом и другими гемобластозами. Утвержден приказом МЗиСР РФ от 14 ноября 2007 г. №704.
2. O’Brien S, Berman E, Borghaei H et al. Chronic Myelogenous Leukemia. Clinical Practice Guidelines in Oncology. JNCCN 2009; 7: 984–1023.
3. Botteman M, Stephens J, Carpiuc K, Feng W. Projecting the Long-Term Quality-Adjusted Survival of Patients with Imatinib-Resistant Chronic Myelogenous Leukemia in Chronic Phase Receiving Nilotinib, Dasatinib, Dose Escalation Imatinib, or Palliative Care: An Essential Element for Cost-Effectiveness Analysis. Blood (ASH Annual Meeting Abstracts) 2007; 110: Abstract 4585.
4. Hochhaus A, Druker BJ, Larson R et al. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Am Soc Hematol Annu Meet Abstr 2007; 110: 15.
5. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540–6.
6. Hendler J, Weitzman A, Haque A, Zheng M. Imatinib-resistant/intolerant Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or Accelerated Phase (AP). Summary of Clinical Efficacy in CML-CP or CML-AP. 2007.
7. Weitzman A, Hendler J, Rafferty T et al. A Phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patiens with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast cristis, relapsed/refractory Ph+ALL, and other hematologic malignancies//Study № CAMN107A2101; Phase II component, imatinib-resistant/intolerant CML-chronic phase. 2006. (Novartis Clinical Study Report).
8. Weitzman A, Rafferty T, Haque A et al. A Phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patiens with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast cristis, relapsed/refractory Ph+ALL, and other hematologic malignancies//Study № CAMN107A2101; Phase II component, imatinib-resistant/intolerant CML-accelerated phase. 2006 (Novartis Clinical Study Report).
9. Hazarika M, Xiaoping Jiang, Qi Liu et al. Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome-Positive ChronicMyelogenous Leukemia Resistant to or Intolerant of Imatinib. Clin Cancer Res 2008; 5325 14 (17): 5325–31.
10. Менделеева Л.П., Савченко В.Г., Любимова Л.С. и др. Состояние проблемы трансплантации гемопоэтических клеток в России (Отчет межрегионального регистра за 1996–2006 гг.). Онкогематология. 2007; 3: 38–45.
11. Life tables for WHO Member States. Russian Federation. 2006. (www.who.int)
12. Астон Консалтинг. Госпитальный аудит. 1–3 кв. 2009 г.
13. Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2010 г. (www.spboms.ru)
14. Kantarjian H, O'Brien S, Talpaz M et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007; 1–7.
15. Schrover RJ, Adena MA, De Abreu LR et al. Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase. Leuk. Lymphoma 2006; 47 (6): 1069–81.
16. Туркина А.Г., Виноградова О.Ю., Хорошко Н.Д., Воробьев А.И. Регистр больных хроническим миелолейкозом в Российской Федерации. Гематол. и трансфузиол. 2007; 2: 7–11.
17. Reed SD, Anstrom KJ, Ludmer JA et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2004; 101 (11): 2574–83.
18. Jabbour E, Kantarjian H, Jones D et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009; 113 (10): 2154–60.
19. Milojkovic D, Nicholson E, Apperley JF et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010; 95: 224–31.